Ligand Pharmaceuticals Inc. (LGND) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Ligand Pharmaceuticals Inc. (LGND:NASDAQ), powered by AI.

Current Price
$255.25
Sector
Healthcare
What is the Ligand Pharmaceuticals Inc. stock price forecast?

Ligand Pharmaceuticals Inc. is currently trading at $255.25. View real-time AI analysis on Alpha Lenz.

What is Ligand Pharmaceuticals Inc. insider trading activity?

View the latest insider trading data for Ligand Pharmaceuticals Inc. on Alpha Lenz.

What is Ligand Pharmaceuticals Inc.'s P/E ratio?

View Ligand Pharmaceuticals Inc.'s valuation metrics on Alpha Lenz.

Ligand Pharmaceuticals Inc.

NASDAQ · LGND
$255.25+2.00(+0.79%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Ligand Pharmaceuticals Inc.'s future dividend policy...
Alpha Chat Insight

Ligand Pharmaceuticals Inc.'s ROE is 13.5%. Explore profitability and growth together.

Ask for details

Company Overview

Ligand Pharmaceuticals Inc. is a biopharmaceutical company that specializes in developing technologies and assets that aid in the discovery process and production of vital therapeutic drugs. The company's primary function is to support pharmaceutical innovation through its proprietary technology platforms, including Captisol, a chemically modified cyclodextrin used to improve the solubility and stability of drugs. Ligand operates in a diverse range of therapeutic areas, placing significant impact on industries related to oncology, inflammation, and infectious diseases, enhancing the effectiveness and delivery of treatments. Noteworthy for its business model, Ligand does not focus on manufacturing its own complete lines of medicines. Instead, it partners with a wide array of pharmaceutical companies, licensing its technologies to advance drug development, thus generating a stream of royalty and milestone revenues. Headquartered in San Diego, California, Ligand Pharmaceuticals plays a critical role in the drug development pipeline, enabling and expediting the creation of revolutionary medical solutions that save lives while maintaining a flexible and diversified portfolio of healthcare investments.

CEOMr. Todd C. Davis Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees68

Company Statistics

FY 2025

Profile

N/AMarket Cap
$268.09MRevenue
0.00Shares Out
68Employees

Margins

94.57%Gross
35.27%EBITDA
17.61%Operating
59.29%Pre-Tax
46.42%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

10.96%Rev 3Yr
10.39%Rev 5Yr
149.55%Op Inc 3Yr
18.28%Op Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

9.95%ROA
13.47%ROE
13.08%ROIC

Financial Health

$174.93MCash & Cash Equivalents
$368.50MNet Debt
53.42%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Ligand Pharmaceuticals Inc. (ticker: LGND) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 68 employees.

The current price is $255.25 with a P/E ratio of -x and P/B of -x.

ROE is 13.47% and operating margin is 17.61%. Annual revenue is $268M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Ligand Pharmaceuticals Inc. (LGND) Stock Forecast 2026 $255.25 — Price, Financials & Analyst Targets | Alpha Lenz